AU2011224238B2 - Parenteral formulations of macrolide antibiotics - Google Patents

Parenteral formulations of macrolide antibiotics Download PDF

Info

Publication number
AU2011224238B2
AU2011224238B2 AU2011224238A AU2011224238A AU2011224238B2 AU 2011224238 B2 AU2011224238 B2 AU 2011224238B2 AU 2011224238 A AU2011224238 A AU 2011224238A AU 2011224238 A AU2011224238 A AU 2011224238A AU 2011224238 B2 AU2011224238 B2 AU 2011224238B2
Authority
AU
Australia
Prior art keywords
composition
cem
another embodiment
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011224238A
Other languages
English (en)
Other versions
AU2011224238A1 (en
Inventor
Prabhavathi Fernandes
David E. Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of AU2011224238A1 publication Critical patent/AU2011224238A1/en
Application granted granted Critical
Publication of AU2011224238B2 publication Critical patent/AU2011224238B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2011224238A 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics Ceased AU2011224238B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31241710P 2010-03-10 2010-03-10
US61/312,417 2010-03-10
PCT/US2011/027984 WO2011112864A1 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Publications (2)

Publication Number Publication Date
AU2011224238A1 AU2011224238A1 (en) 2012-10-04
AU2011224238B2 true AU2011224238B2 (en) 2015-11-26

Family

ID=44563855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011224238A Ceased AU2011224238B2 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Country Status (11)

Country Link
US (3) US20130045937A1 (enExample)
EP (1) EP2544537B1 (enExample)
JP (1) JP5890785B2 (enExample)
CN (2) CN102811616A (enExample)
AU (1) AU2011224238B2 (enExample)
CA (1) CA2792616A1 (enExample)
DK (1) DK2544537T3 (enExample)
ES (1) ES2637072T3 (enExample)
PL (1) PL2544537T3 (enExample)
SI (1) SI2544537T1 (enExample)
WO (1) WO2011112864A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9072759B2 (en) 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
ES2564097T3 (es) 2010-03-22 2016-03-17 Cempra Pharmaceuticals, Inc. Formas cristalinas de un macrólido, y usos de las mismas
ES2636948T3 (es) 2010-05-20 2017-10-10 Cempra Pharmaceuticals, Inc. Procesos para preparar macrólidos y cetólidos e intermediarios para los mismos
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
IN2014DN08939A (enExample) * 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CN105163785A (zh) * 2013-03-14 2015-12-16 森普拉制药公司 用于治疗呼吸道疾病的方法及其制剂
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
US10098834B2 (en) 2013-05-22 2018-10-16 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758922A (zh) * 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CA2957034A1 (en) * 2014-08-05 2016-02-11 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
WO2016057798A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN107530365A (zh) 2015-03-25 2018-01-02 哈佛大学的校长及成员们 具有修饰的脱氧糖胺糖的大环内酯及其用途
CA3144443A1 (en) * 2019-06-28 2020-12-30 Moleculin Biotech, Inc. Method of reconstituting liposomal annamycin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents
US20080221048A1 (en) * 2004-03-17 2008-09-11 App Pharmaceuticals, Llc. Lyophilized azithromycin formulation
US20090156517A1 (en) * 2006-08-25 2009-06-18 Hesheng Zhang Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
WO2003072141A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents
US20080221048A1 (en) * 2004-03-17 2008-09-11 App Pharmaceuticals, Llc. Lyophilized azithromycin formulation
US20090156517A1 (en) * 2006-08-25 2009-06-18 Hesheng Zhang Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers

Also Published As

Publication number Publication date
EP2544537A1 (en) 2013-01-16
ES2637072T3 (es) 2017-10-10
JP5890785B2 (ja) 2016-03-22
JP2013522229A (ja) 2013-06-13
CN109091489A (zh) 2018-12-28
WO2011112864A1 (en) 2011-09-15
EP2544537B1 (en) 2017-05-10
CA2792616A1 (en) 2011-09-15
US20200276150A1 (en) 2020-09-03
SI2544537T1 (sl) 2017-12-29
EP2544537A4 (en) 2014-05-14
CN102811616A (zh) 2012-12-05
AU2011224238A1 (en) 2012-10-04
DK2544537T3 (en) 2017-08-28
US20190054059A1 (en) 2019-02-21
PL2544537T3 (pl) 2017-10-31
US20130045937A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
AU2011224238B2 (en) Parenteral formulations of macrolide antibiotics
JP6378408B2 (ja) マクロライド抗生物質を投与するための非経口製剤
CN101045063B (zh) 注射用克拉霉素水溶性制剂
HK1180184B (en) Parenteral formulations of macrolide antibiotics
HK1180184A (en) Parenteral formulations of macrolide antibiotics
HK40002820A (en) Parenteral formulations of macrolide antibiotics
HK1179115A (en) Parenteral formulations of macrolide antibiotics
AU2018220172A1 (en) Triazole-containing macrolides and ophthalmic uses therefor
HK1208622B (zh) 用於施用大环内酯抗生素的肠胃外制剂
AU2018230347A1 (en) Compositions and methods for treating dry eye diseases

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PEREIRA, DAVID E. AND FERNANDES, PRABHAVATHI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired